Genetic Engineering in the Press by GEG

At the 2015 meeting of the American Society of Hematology (ASH), blood specialists mulled over 270 presentations on this condition, what’s now formally termed sickle cell disease. On December 6, experts discussed three new reports on other, more feasible approaches to managing sickle cell disease (SCD), two of which may soon be practice-changing: one on hydroxyurea to reduce the risk of stroke in affected children, and one on results of sibling-matched bone marrow transplantation in 1,000 affected individuals with severe disease. A third report detailed an early-phase study of an experimental pill, GBT440 (Global Blood Therapeutics), that may relieve SCD symptoms and organ damage by increasing hemoglobin’s binding of oxygen.

http://www.forbes.com/sites/elaineschattner/2015/12/15/the-big-news-for-sickle-cell-anemia-is-not-gene-therapy/